CEBPA and acute myeloid leukemia: NRAS p.G12D (Patient 2), CEBPA p.Q312dup (Patient 3), FLT3 p.T526M (Patient 4), IDH2 p.R140Q (Patient 5), CEBPA p.Q346fs*10 (Patient 6) and CEBPA p.V343fs*11 (Patient 6) were among mutations in known AML driver genes that were retained after chemotherapy with VAF of 14.4%, 87.6%, 48.5%, 38.7%, 42.9 and 43.5%, respectively, in the presentation samples and 33.4%, 47.0%, 48.8%, 26.1%, 49.6 and 47.4% in the relapse samples.